Evidence map›Paper›PMID 37668866›Full record

ArticleRheumatology and therapy2023

Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.

Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaçi, Thilo Klopsch, Anja Plenske, Lisa K Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Löschmann

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Rheumatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Eugen FeistDepartment of Rheumatology, Helios Fachklinik, Sophie-von-Boetticher-Straße 1, 39245, Vogelsang-Gommern, Germany. eugen.feist@helios-gesundheit.de.ORCID http://orcid.org/0000-0002-9872-5282
Xenofon BaraliakosRheumatology Center Ruhrgebiet Herne, Ruhr-University, Bochum, Germany.ORCID http://orcid.org/0000-0002-9475-9362
Frank BehrensCIRI/Rheumatology and Fraunhofer IME, Institute for Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt/Main, Germany.ORCID http://orcid.org/0000-0001-8750-7186
Diamant ThaçiInstitute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.ORCID http://orcid.org/0000-0001-8513-550X
Thilo KlopschRheumatology Practice, Neubrandenburg, Germany.
Anja PlenskePfizer Pharma GmbH, Berlin, Germany.
Lisa K BlindzellnerPfizer Pharma GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0002-6203-5095
Pascal KlausPfizer Pharma GmbH, Berlin, Germany.
Thomas MengPfizer Pharma GmbH, Berlin, Germany.
Peter-Andreas LöschmannPfizer Pharma GmbH, Berlin, Germany.ORCID http://orcid.org/0000-0002-3518-0174
Pfizer (Germany) · DEGoethe University Frankfurt · DEHelios Kliniken · DERheumazentrum Ruhrgebiet · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37668866
PMCPMC10654265
OpenAlexW4386437838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.